CONFERENCES

      Japanese Society for Pharmacoepidemiology Meeting

      This is an annual conference by Japanese Society for Pharmacoepidemiology (JSPE) that focuses on the rational use of medicines and medical devices, with topics ranging from epidemiological methodologies to regulatory science. The conference is aimed at researchers, scientists, and professionals in the field of pharmacoepidemiology, and provides a forum for sharing knowledge and collaborating on new approaches in the field. 

      27th Annual Meeting of JSPE 2022

      Date

      Nov 17, 2022 - Nov 19, 2022

      Location

      Kobe, Japan

      This event, which has for theme "Redefining Pharmacoepidemiology", includes presentations on the quantitative and qualitative changes in pharmacoepidemiology caused by the use of medical big data.

      26th Annual Meeting of JSPE 2021

      Date

      Nov 26, 2021 - Nov 28, 2021

      Location

      Tokyo, Japan

      Online

      This event, which has for theme "Regulatory Science Meets Epidemiology", includes presentations on the use and mission of drug epidemiology in the development life cycle of pharmaceuticals and medical devices, including from the perspective of regulatory science.

      24th Annual Meeting of JSPE 2018

      Date

      Oct 13, 2018 - Oct 14, 2018

      Location

      Sendai, Japan

      At this event, PMI scientists present the research on the introduction of smoke-free products into the Japanese market and their impact on public health.

      See related presentations

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.